{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=31", "query": { "condition": "Pharmacokinetics and Pharmacodynamics", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 2339, "total_pages": 234, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T17:09:20.516Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00382798", "title": "Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy Volunteers", "Hepatitis C Virus" ], "interventions": [ { "name": "RO5024048", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmasset", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2006-10", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2009-04-27", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00382798" }, { "nct_id": "NCT00749411", "title": "Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "GSK233705/GW642444", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 61, "start_date": "2008-11-13", "completion_date": "2009-02-12", "has_results": true, "last_update_posted_date": "2020-09-01", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 12, "location_summary": "Mobile, Alabama • Wheat Ridge, Colorado • Biddeford, Maine + 9 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Biddeford", "state": "Maine" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Summit", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749411" }, { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT03224819", "title": "Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Emerfetamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2017-09-07", "completion_date": "2020-12-28", "has_results": true, "last_update_posted_date": "2023-09-01", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Duarte, California • Houston, Texas + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03224819" }, { "nct_id": "NCT02524782", "title": "A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "MEDI-4166", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 103, "start_date": "2015-10-07", "completion_date": "2017-04-14", "has_results": false, "last_update_posted_date": "2019-03-13", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 11, "location_summary": "Anniston, Alabama • Chula Vista, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02524782" }, { "nct_id": "NCT02622334", "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glaucoma" ], "interventions": [ { "name": "Latanoprost", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO5093151", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2015-12-29", "completion_date": "2016-07-28", "has_results": false, "last_update_posted_date": "2018-03-14", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 6, "location_summary": "Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Morrow", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02622334" }, { "nct_id": "NCT02878616", "title": "Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "LFG316", "type": "DRUG" }, { "name": "IVIG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2016-08-26", "completion_date": "2017-07-19", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02878616" }, { "nct_id": "NCT04302064", "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Eplontersen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "20 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2020-04-23", "completion_date": "2020-09-10", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302064" }, { "nct_id": "NCT07192614", "title": "A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AZD6621", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 52, "start_date": "2025-09-30", "completion_date": "2029-03-29", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 6, "location_summary": "Orlando, Florida • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07192614" }, { "nct_id": "NCT01497821", "title": "AMG 172 First in Human Study in Patients With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Adenocarcinoma", "Clear Cell Renal Carcinoma", "Clear Cell Renal Cell Carcinoma", "Renal Cell Carcinoma" ], "interventions": [ { "name": "AMG 172", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-01", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2016-03-25", "last_synced_at": "2026-10-16T17:09:20.516Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • St Louis, Missouri", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497821" } ] }